$LOAC News
Last published 5y ago
- 5y agoLBPSLOAC4D pharma Announces Completion of Merger With Longevity Acquisition CorporationBusiness WireLEEDS, England--(BUSINESS WIRE)--4D pharma plc (Nasdaq: LBPS; AIM: DDDD) ("4D pharma" or the "Company"), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome - today announced completion of its merger (“the Merger”) with Longevity Acquisition Corporation ("Longevity")(Nasdaq: LOAC).
- 5y agoLOACLongevity Acquisition Corporation Announces Results of Special Meeting of ShareholdersPR NewswireLongevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today the results...
- 5y agoLOAC4D Pharma Announces Private PlacementBusiness WireLEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD) ("4D" or the "Company"), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces it has entered into Securities Purchase Agreements with a select group of U.S. and United Kingdom institutional investors and accredited investors to raise, in ...
- 5y agoLOAC4D Pharma to Present at Upcoming Investor Conferences in MarchBusiness WireLEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announced that 4D management will present at three upcoming investor conferences:
- 5y agoLOAC4D Pharma Appoints John Beck as Chief Financial Officer and Member of the Management TeamBusiness WireLEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces the appointment of John Beck as Chief Financial Officer (CFO) and member of the Company’s management team, bringing over 30 years of experience in finance, including three previous po ...
- 5y agoLOAC4D Pharma Announces U.S. SEC Declares Registration Statement Effective with Respect to the Issuance of 4D Pharma American Depositary Shares on NASDAQBusiness WireLEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces that the United States Securities and Exchange Commission (“SEC”) has declared effective its registration statements on Form F-4 with respect to the issuance of 4D pharma American Dep ...
- 5y agoLOACLongevity Acquisition Corporation Announces 4D pharma Clinical Trial Collaboration and Supply Agreement for the Treatment of Locally Advanced or Metastatic Urothelial CarcinomaPR NewswireLongevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today that on...
- 5y agoLOAC4D pharma Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate MRx0518 in Combination with BAVENCIO® for the Treatment of Locally Advanced or Metastatic Urothelial CarcinomaBusiness WireLEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announced a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc. for BAVENCIO® (avelumab), the first and only immunotherapy approved as a first-l ...
- 5y agoLOACLongevity Acquisition Corporation Announces 4D pharma Update on Oncology ProgramPR NewswireLongevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today that on...
- 5y agoLOAC4D Pharma Presents Update on Oncology ProgramBusiness WireLEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces progress on activities in its development program for lead immuno-oncology single strain Live Biotherapeutic candidate MRx0518.
- 5y agoLOACLongevity Acquisition Corporation Announces 4D pharma Joining Landmark Parkinson's Progression Markers InitiativePR NewswireLongevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today that on...
- 5y agoLOACLongevity Acquisition Corporation Regains Compliance with Nasdaq Listing RequirementPR NewswireLongevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today that on...
- 5y agoLOAC4D pharma plc Files SEC Forms in Process to Gain NASDAQ Listing Following Merger with Longevity, a Special Purpose Acquisition Company (SPAC)Business WireLEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces the filing of a registration statement on Form F-4 (the “Registration Statement”) with the US Securities and Exchange Commission (SEC). The filing follows the announcement on October ...
- 5y agoLOACLongevity Acquisition Corporation Announces Extension of Deadline to Complete a Business CombinationPR NewswireLongevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today that it has...
- 5y agoLOACLongevity Acquisition Corporation Announces Increased Cash Contribution for the ExtensionPR NewswireLongevity Acquisition Corporation (NASDAQ: LOAC) (the "Company" or "LOAC"), a publicly-traded special purpose acquisition company (SPAC), announced...
- 6y agoLOAC4D Pharma Presents New Data from Two MRx0518 Clinical Trials at the Society for Immunotherapy of Cancer (SITC) Annual MeetingBusiness WireLEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces new positive clinical data from two clinical trials of MRx0518, its lead immuno-oncology single strain Live Biotherapeutic candidate. The data is presented in three posters at the Soc ...
- 6y agoLOAC4D Pharma to Host Virtual KOL Event Reviewing New Data Presented at the Society for Immunotherapy of Cancer Annual Meeting 2020 from Live Biotherapeutic MRx0518 Clinical ProgramsBusiness WireLEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces that it will host a virtual Key Opinion Leader (KOL) event to review data presented from two ongoing clinical trials of MRx0518, the Company’s lead immuno-oncology single strain Live ...
- 6y agoLOACLongevity Acquisition Corporation Announces Signing of Definitive Merger AgreementPR NewswireLongevity Acquisition Corporation (NASDAQ: LOAC) (the "Company" or "LOAC"), a publicly-traded special purpose acquisition company (SPAC), announced...
- 6y agoLOACLongevity Acquisition Corporation Announces Extension of Deadline to Complete a Business CombinationPR NewswireLongevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today that it has...